Life Chemicals and Variational AI have joined forces to tackle one of oncology’s toughest challenges: overcoming resistance through selective dual inhibition.
Using the Enki™ Lead Generator for de novo design and Life Chemicals’ synthesis expertise, the collaboration delivered first-in-class dual EGFR/FGFR1 kinase inhibitors.
Key outcomes:
- Lead candidate: 29 nM (EGFR) / 175 nM (FGFR1) with excellent selectivity
- All scaffolds confirmed as novel frameworks (≤0.5 Tanimoto similarity)
This success highlights the power of AI-driven molecular design combined with rapid custom synthesis.
AI-Driven, Custom-Tailored Libraries for Your Target
Building on this success, we offer flexible solutions for designing and delivering novel small-molecule libraries:
✔ Generative AI with Enki™ to explore novel chemical space beyond known scaffolds
✔ In silico compound selection via docking, pharmacophore refinement by our expert cheminformatics team
✔ Proprietary HTS collection of 575,000+ in-stock drug-like compounds, ready for screening
✔ Custom synthesis services for rapid preparation of new molecules and hit expansion
From virtual screening to synthesis to screening-ready plates, Life Chemicals empowers drug discovery teams to accelerate hit identification for kinases, GPCRs, proteases, and beyond.
Partner with us today to create a custom screening library tailored to your target and unlock new opportunities in drug discovery. Contact us for details at marketing@lifechemicals.com.
The Drug discovery workflow using Enki™
The docking overlays of the blinded ligand in yellow to the EGFR and FGFR1 kinase binding site.
